Bevenopran (INN, USAN) (former developmental code names CB-8635, ADL-8635, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.[1][2][3] It reached phase III clinical trials for this indication before being discontinued.[4][5]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H26N4O4 |
Molar mass | 386.452 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF (2011). "Novel opioid antagonists for opioid-induced bowel dysfunction". Expert Opin Investig Drugs. 20 (8): 1047–56. doi:10.1517/13543784.2011.592830. PMID 21663526. S2CID 207475985.1047-56&rft.date=2011&rft_id=https://api.semanticscholar.org/CorpusID:207475985#id-name=S2CID&rft_id=info:pmid/21663526&rft_id=info:doi/10.1517/13543784.2011.592830&rft.aulast=Diego&rft.aufirst=L&rft.au=Atayee, R&rft.au=Helmons, P&rft.au=Hsiao, G&rft.au=von Gunten, CF&rfr_id=info:sid/en.wikipedia.org:Bevenopran" class="Z3988">
- ^ Siemens W, Gaertner J, Becker G (2015). "Advances in pharmacotherapy for opioid-induced constipation - a systematic review". Expert Opin Pharmacother. 16 (4): 515–32. doi:10.1517/14656566.2015.995625. PMID 25539282. S2CID 34614812.515-32&rft.date=2015&rft_id=https://api.semanticscholar.org/CorpusID:34614812#id-name=S2CID&rft_id=info:pmid/25539282&rft_id=info:doi/10.1517/14656566.2015.995625&rft.aulast=Siemens&rft.aufirst=W&rft.au=Gaertner, J&rft.au=Becker, G&rfr_id=info:sid/en.wikipedia.org:Bevenopran" class="Z3988">
- ^ Annual Reports in Medicinal Chemistry. Elsevier Science. 13 September 2013. pp. 451–. ISBN 978-0-12-417151-0.
- ^ Combating Opioid-Induced Constipation: New and Emerging Therapies
- ^ Bevenopran